For FA anabolic enzymes (table 2), increased expression of FASN was correlated with unfavorable OS in stage II, III, and IV ccRCC patients (HR 95% CI=3.33 (1.10-10.09), 2.25 (1.27-3.97), and 2.74 (1.66-4.53), respectively), while there was no difference in stage I ccRCC patients (P>0.05). The gene discussed is FASN; the disease is nonpapillary renal cell carcinoma.